Tocilizumab
2 NDCs across 1 manufacturer|0 Generic,2 Brand
Tocilizumab is used to treat juvenile arthritis, rheumatoid arthritis, cytokine release syndrome and giant cell arteritis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $368 million on Tocilizumab across 91,000 claims for 14,000 beneficiaries.
Tocilizumab is available as 2 NDCs from 1 manufacturer (0 generic, 2 brand), with NADAC prices from $1001.12 to $1279.06 per ML — a 28% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
0G / 2B
Manufacturers
1
competing in market
Price Spread
$1001.12 – $1279.06
per ML
7d Activity
avg +0.0% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing TOCILIZUMAB
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
ACTEMRA ACTPEN 162 MG/0.9 ML | $1279.0578 per ML | — |
ACTEMRA 162 MG/0.9 ML SYRINGE | $1001.1205 per ML | — |
Frequently Asked Questions
What is Tocilizumab used to treat?
Tocilizumab is used to treat juvenile arthritis, rheumatoid arthritis, cytokine release syndrome and giant cell arteritis, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Tocilizumab?
In 2024, Medicare Part D spent $368 million on Tocilizumab across 91,000 claims for 14,000 beneficiaries.
How many Tocilizumab products are on the market?
The Tocilizumab drug market contains 2 NDCs from 1 manufacturer — 0 generic and 2 brand products.
What is the price range for Tocilizumab?
NADAC reference prices for Tocilizumab range from $1001.1205 to $1279.0578 per ML — a 28% difference between cheapest and most expensive.
Which manufacturers make Tocilizumab?
1 manufacturer lists Tocilizumab in NADAC. Ranked by number of NDCs, the largest are Genentech, Inc. (2).